Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹153 Cr
Revenue (TTM)
₹391 Cr
Net Profit (TTM)
₹3 Cr
ROE
3 %
ROCE
6.4 %
P/E Ratio
44.6
P/B Ratio
1.1
Industry P/E
44.74
EV/EBITDA
15.5
Div. Yield
0 %
Debt to Equity
0.3
Book Value
₹51.3
EPS
₹1.2
Face value
10
Shares outstanding
28,354,303
CFO
₹1.48 Cr
EBITDA
₹62.53 Cr
Net Profit
₹50.82 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aarey Drugs
| -20.6 | -30.0 | -20.5 | 45.7 | 30.8 | -- | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Aarey Drugs
| 17.6 | -5.9 | 30.8 | -10.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aarey Drugs
|
53.7 | 153.3 | 390.9 | 3.4 | -0.5 | 2.4 | 44.6 | 1.1 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di... methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company trades chemicals and solvents, including aromatic chemicals, chemical acids, chlor-alkali, glycols and glycol ethers, fiber intermediates, and acetates and esters, as well as industrial alcohols, ketones, amines, oleochemicals, intermediates, olefins, phosphates, fertilizers, monomers, and chemicals. It serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India. Read more
Incorporated
1990
Chairman
Mihir R Ghatalia
Managing Director
Mihir R Ghatalia
Group
Aarey
Headquarters
Thane, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Aarey Drugs & Pharmaceuticals Ltd is ₹53.71 (NSE) and ₹54.07 (BSE) as of 02-Apr-2026 IST. Aarey Drugs & Pharmaceuticals Ltd has given a return of 30.8% in the last 3 years.
The P/E ratio of Aarey Drugs & Pharmaceuticals Ltd is 44.62 times as on 02-Apr-2026, a 0 discount to its peers’ median range of 44.74 times.
The P/B ratio of Aarey Drugs & Pharmaceuticals Ltd is 1.05 times as on 02-Apr-2026, a 66 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
23.84
|
0.71
|
|
2024
|
26.76
|
0.96
|
|
2023
|
15.93
|
0.52
|
|
2022
|
16.03
|
0.94
|
|
2021
|
8.33
|
0.56
|
The 52-week high and low of Aarey Drugs & Pharmaceuticals Ltd are Rs 100.00 and Rs 38.01 as of 05-Apr-2026.
Aarey Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹ 153 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aarey Drugs & Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.43
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.